about
Corticosteroids for myasthenia gravisDiagnostic support for selected neuromuscular diseases using answer-pattern recognition and data mining techniques: a proof of concept multicenter prospective trial.Current and future standards in treatment of myasthenia gravisThe brain in myotonic dystrophy 1 and 2: evidence for a predominant white matter disease.Expansion of CUG RNA repeats causes stress and inhibition of translation in myotonic dystrophy 1 (DM1) cellsNeuroleptic malignant syndrome in Kufs' disease.RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime SleepinessSudden cardiac death in myotonic dystrophy type 2.Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroimmunological diseases.GSK3β mediates muscle pathology in myotonic dystrophyReduction of the rate of protein translation in patients with myotonic dystrophy 2Glia cells in amyotrophic lateral sclerosis: new clues to understanding an old disease?Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patientsGrey and white matter loss along cerebral midline structures in myotonic dystrophy type 2.CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2.Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1.Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative 31P-MRS and MRI study.Late-onset myopathy of the posterior calf muscles mimicking Miyoshi myopathy unrelated to dysferlin mutation: a case report.Side effects of anesthesia in DM2 as compared to DM1: a comparative retrospective study.Creatine monohydrate in DM2/PROMM: a double-blind placebo-controlled clinical study. Proximal myotonic myopathy.Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography.Unusual Charcot-Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin protein zero.Successful treatment of anti-Caspr2 syndrome by interleukin 6 receptor blockade through tocilizumab.Muscle pathology in 57 patients with myotonic dystrophy type 2Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A)SonoGraphic monitoring of severe focal B-cell myositis of the anterior calf muscle responsive to rituximabPhenotypic spectrum of PINK1-associated parkinsonism in 15 mutation carriers from 1 familyClinical Spectrum of Homozygous and Heterozygous PINK1 Mutations in a Large German Family With Parkinson DiseaseSubcutaneous immunoglobulin infusion: A new therapeutic option in chronic inflammatory demyelinating polyneuropathyLGMD 2I due to the common mutation 826C>A in the FKRP gene presenting as myopathy with vacuoles and paired-helical filamentsPregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndromeMuskuloskelettaler Schmerz als Hauptsymptom bei myotoner Dystrophie Typ 2Outcome and effect of pregnancy in myotonic dystrophy type 2Musculoskeletal Pain in Patients With Myotonic Dystrophy Type 2Myasthenia gravisOculomotor signs in Lambert-Eaton myasthenic syndrome?coincidence with myasthenia gravis
P50
Q24244116-43231D3D-A07B-43FC-88FB-E17E866ABF7CQ31055021-7EE07744-DC44-490B-9F13-12053F567CE6Q34014734-A7F69709-0655-448C-8848-6BFC12A97B1EQ34087408-A0DC172D-2F21-440B-8E90-63739A9C9EFFQ34378929-2E7DBCE7-87F4-4DC9-8245-E5F4DE4B0441Q35472036-05DA84C1-9623-4B58-8422-AD20E1AB8980Q35474587-07ECF61B-EEF1-400D-8218-D1D84FA2C68BQ35675290-DBA74B23-828B-4D39-AF12-3417EFE35208Q35995815-CA8B6B90-CAA5-4B2D-82F8-3BC7CF9FF08FQ36438898-487BC22E-AE7E-483D-9148-B9C8212D0A57Q36498042-352E6119-1C54-48AF-A3E8-2D82B4D7A19CQ36723012-69970BDA-6190-45A3-954C-64193A47292DQ36764835-7C31689B-E5F5-467D-90D5-61FD796D6595Q37278485-8C89E62E-94F9-4DC6-899A-A28635D4CC0CQ37405612-BD6A20F9-9ABC-4B08-B6B9-C93B5532C17AQ37748722-86E76D3A-093F-4AE3-A3AB-D4B69DF42466Q39969644-F7AC2273-9E2E-44F4-B20B-A82E09CCA9B7Q40479410-8212C183-240E-45C3-8BD5-EF8F255B843EQ41608436-98D7FDA7-28B8-4A62-A493-4050C26E5E33Q43435548-90EC8332-9D2A-497B-8696-089EF6043C6AQ44310111-3D03E2D3-977F-42F1-8283-D64656FDFE27Q48178005-C5D3DA2B-F876-4B6E-829C-6C849CA77380Q48666831-5F1233BB-2514-4A43-843D-85A0AECBD123Q50896549-7D1B3767-8B57-4C06-8864-01E9EA605697Q57390260-737AD558-85FC-42FE-8F35-4D4DA6E6A52CQ57908829-329C272D-82AB-4F12-BBE8-6B7C875519FCQ58001727-8EE349D4-B9A8-4717-AB12-0B3D7CC73A02Q60332321-CA56C99D-F0C1-46F4-A7DB-97351CF88A98Q60332322-771BD321-329A-41B7-8C03-27583981C528Q60594481-119F8816-7A04-40DB-9777-7B3BFC46CBF5Q60594482-12E86634-DBF9-479E-A96B-A69FE5486B2CQ60594483-C49C2BA4-792E-48F1-94C8-08A4F4DB849EQ60594484-83B2800D-BCD0-4A71-BFFF-813D740AF2F3Q60594485-38EFBA88-1D5B-4207-8E3C-6BCFD09079B5Q60594486-1978B929-ED9D-4B39-A7B0-BCB1B1E5ECACQ60594487-1D17B5CD-C95E-4F48-BF97-54CA99CD0B6CQ60594488-F3BD76F1-F84B-4BE4-BD7A-58893D3ABD08
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christiane Schneider-Gold
@ast
Christiane Schneider-Gold
@en
Christiane Schneider-Gold
@es
Christiane Schneider-Gold
@nl
Christiane Schneider-Gold
@sl
type
label
Christiane Schneider-Gold
@ast
Christiane Schneider-Gold
@en
Christiane Schneider-Gold
@es
Christiane Schneider-Gold
@nl
Christiane Schneider-Gold
@sl
prefLabel
Christiane Schneider-Gold
@ast
Christiane Schneider-Gold
@en
Christiane Schneider-Gold
@es
Christiane Schneider-Gold
@nl
Christiane Schneider-Gold
@sl
P106
P21
P31
P496
0000-0002-9232-201X